ANXA2 and neoplasm: Because ANXA2 is a functionally relevant protein, specifically in tumor cells with a high metastatic potential, it is conceivable that PDAC tumor cells would not be able to evade antitumor T cell immunity through antigen loss if ANXA2 is the antigen used for a Listeria-based immunotherapy.